Arcturus Therapeutics Holdings Inc. (ARCT) Dividend History

Company News

• RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding

  The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%, driven by advancements in RNA technologies and next-generation therapies.

  GlobeNewswire Inc.

  Featured Companies: ATYR
• European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

  The European Commission has approved KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. KOSTAIVE is the first of its kind to receive approval in Europe and has shown superior immunogenicity and antibody persistence compared to conventional mRNA vaccines.

  Benzinga
• Arcturus: A Hidden Gem In The Biotech Sector

  Arcturus, a leading biotech company, is a top pick in the market with innovative vaccines, strong revenue generation, and promising growth. Read more here.

  Seeking Alpha
• Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

  Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Zacks Investment Research
• Why Shares of Arcturus Therapeutics Dropped on Tuesday

  The company saw revenue decline and net losses rise in the second quarter.

  The Motley Fool